Multiple Sclerosis
Multiple sclerosis is a chronic disease in which the immune system mistakenly attacks the central nervous system, especially the brain, spinal cord, and optic nerves. The most immediate damage is to myelin, the fatty insulating layer that wraps around nerve fibers and helps electrical signals travel quickly and efficiently. Think of it like the rubber that insulates a copper wire. When myelin is damaged, communication through the nervous system becomes slower, less reliable, or blocked altogether.
MS often begins in early to middle adulthood and is more common in women than men. Symptoms vary widely depending on which parts of the nervous system are affected, but can include vision problems, numbness, weakness, imbalance, fatigue, and cognitive changes. One reason MS can be confusing at first is that it does not look the same in every person. Some people have clear attacks followed by recovery, while others gradually worsen over time.
Although MS is classically described as an inflammatory demyelinating disease, that is only part of the story. Over time, damage to myelin can expose and stress the underlying axons, the long projections that neurons use to communicate. This means MS is not just about immune attacks and myelin loss. It can also become a disease of progressive neurodegeneration, especially in later stages.
Pathology
The best-known pathological feature of MS is the formation of lesions in areas where myelin has been damaged. These lesions can occur in different parts of the central nervous system and are caused by inflammatory immune activity directed against myelin and the cells that make it (oligodendrocytes). In active lesions, immune cells enter or become activated within the central nervous system and drive tissue injury.
Demyelination has immediate functional consequences because myelin is what allows nerve impulses to travel rapidly and efficiently. Without it, signals slow down, fail to arrive, or require much more energy to transmit. That helps explain symptoms such as weakness, visual blurring, sensory changes, or poor coordination. In some cases, the nervous system can partially compensate, especially early on, which is why symptoms sometimes improve after a relapse.
Over time, however, the problem can deepen. Chronic demyelination deprives axons of metabolic and structural support, making them more vulnerable to irreversible injury. Axonal loss and neuronal degeneration are major contributors to long-term disability, especially in progressive MS. This is one of the most important shifts in how scientists now think about the disease: inflammation may initiate much of the damage, but neurodegeneration is a major driver of lasting decline.
Biological Pathways
The major pathway in MS is immune dysregulation. Immune cells that should normally protect the body and clean up waste instead attack central nervous system tissue. This includes both peripheral immune cells that enter the CNS, like macrophages, and resident immune cells such as microglia that become chronically activated. The result is an inflammatory environment that damages myelin, oligodendrocytes, and eventually axons.
A second core pathway, and the direct result of neuroinflammation in this case, is demyelination and failed remyelination. Early in the disease, the brain and spinal cord can sometimes repair damaged myelin, at least partially. But over time, repair often becomes incomplete or fails altogether. When remyelination does not keep up, axons are left exposed and vulnerable, and the nervous system becomes less functional and more vulnerable to permanent damage.
The third major pathway is axon and neuron loss. Myelin is not just insulation; it also provides support that helps axons survive. As that support breaks down, nerve fibers experience metabolic stress, conduction failure, and eventual degeneration. This is one reason MS can transition from a disease with relapses to one marked by slow accumulation of disability even without obvious new attacks.
Causes
MS is not caused by a single gene or a single exposure. Instead, it appears to arise from a combination of genetic susceptibility and environmental influences that shape immune function over time. Family history can increase risk, but most people with MS do not inherit it in a simple Mendelian pattern.
Environmental risk factors include low vitamin D levels, reduced sun exposure, smoking, and prior infection with Epstein-Barr virus, which has become an especially important focus in MS research. Obesity, particularly earlier in life, has also been linked to increased risk. These factors do not guarantee that someone will develop MS, but they appear to worsten the odds in a susceptible person.
The disease is therefore best understood as an immune-mediated condition that emerges when background susceptibility and environmental triggers line up in the wrong way. That framing helps explain why no single cause applies to every person with MS.
Progression
MS does not progress in exactly the same way for everyone. Many people begin with relapsing-remitting MS, in which episodes of new or worsening symptoms are followed by periods of partial or substantial recovery. Early in the disease, inflammation is often the most visible driver of symptoms.
Over time, some patients transition to a more steadily worsening phase, often called secondary progressive MS. Others have that progression from the beginning, known as primary progressive MS. In these forms, disability may accumulate even when there are fewer obvious relapses, reflecting the growing importance of axonal loss, chronic lesions, and neurodegenerative mechanisms.
This matters because it changes both the patient experience and the treatment challenge. Relapses are easier to see and measure. Slow progression is harder to detect, but it is often what most strongly determines long-term disability.
Treatment Landscape
A large group of disease-modifying therapies now exists to reduce relapses, suppress new inflammatory activity on MRI, and slow the accumulation of disability, especially in relapsing forms of the disease. These therapies do not all work the same way. Some broadly modulate immune activity, while others more specifically target immune cell trafficking or depletion.
That said, current treatments are generally better at controlling inflammation than reversing established damage. They can reduce new attacks and help preserve function, but they are less effective at restoring lost myelin or fully stopping progression once chronic neurodegenerative changes are underway. This is one of the central limitations of the current treatment era.
Supportive care also remains important. Physical therapy, treatment of spasticity, fatigue management, mobility aids, vision care, bladder care, and cognitive support can make a major difference in day-to-day quality of life. In other words, MS treatment is not just about suppressing the immune system. It is also about preserving independence and function over time.
Research Directions
A major research goal in MS is to move beyond inflammation control toward repair and protection. That includes developing therapies that promote remyelination, preserve axons, and slow or prevent the neurodegenerative component of the disease. This is especially important for progressive MS, where current therapies are still less effective than many patients and clinicians would like.
Researchers are also refining the way MS progression is measured. New imaging markers, including chronic active lesion features such as paramagnetic rim or broad rim lesions, are helping scientists better identify the kinds of tissue injury most associated with progression. This may improve both prognosis and clinical trial design.
More broadly, the field is moving toward a fuller view of MS as a disease with at least two intertwined problems: immune-mediated demyelination and neurodegeneration. The next generation of therapies will likely need to address both. Controlling inflammation is necessary, but for many patients it will not be sufficient on its own.
Sources
- Klotz et al. “Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis.” Nature Medicine. 2025.
- Cagol et al. “The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: a systematic review and network meta-analysis.” The Lancet Regional Health Europe. 2025.
- Duncan et al. “Remyelination protects neurons from DLK-mediated neurodegeneration.” Nature Communications. 2024.